Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

7.0K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

744
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
744
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

867
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
867

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dysregulated calcium signaling underlies hyposalivation and microbial dysbiosis in Down syndrome.

Cell reports·2026
Same author

Zegocractin for acute pancreatitis with systemic inflammatory response syndrome: a randomized, controlled, dose-ranging, phase 2b trial.

EClinicalMedicine·2026
Same author

ZIP3 is essential for the encephalitogenic function of pTh17 cells by regulating intracellular zinc levels.

Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)·2026
Same author

Bench to Bedside: Translating Discoveries to Clinical Care in Kidney Disease.

Nephron·2025
Same author

SLC7A5 regulates B cell metabolism and plasma cell differentiation independent of leucine transport.

Journal of immunology (Baltimore, Md. : 1950)·2025
Same author

Age-related decline of chaperone-mediated autophagy in skeletal muscle leads to progressive myopathy.

Nature metabolism·2025

Related Experiment Video

Updated: Apr 25, 2026

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

1.9K

CRAC channels as targets for immunotherapy.

Kenneth Stauderman1, Sudarshan Hebbar1, Stefan Feske2

  • 1CalciMedica Inc., La Jolla, CA 92037, USA.

Current Opinion in Immunology
|April 23, 2026
PubMed
Summary

Calcium release-activated calcium (CRAC) channels are vital for immune cell function and linked to immune disorders. Inhibiting these channels shows promise for treating inflammatory conditions.

More Related Videos

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.9K
Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
09:08

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

1.5K

Related Experiment Videos

Last Updated: Apr 25, 2026

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

1.9K
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.9K
Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
09:08

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

1.5K

Area of Science:

  • Immunology
  • Cell Biology
  • Pharmacology

Background:

  • Calcium release-activated calcium (CRAC) channels regulate store-operated calcium entry in immune and non-immune cells.
  • CRAC channels are critical for immune cell function and implicated in immune-related disorders.
  • Mutations in ORAI1 and STIM1 genes, encoding CRAC channel components, cause inborn errors of immunity.

Purpose of the Study:

  • To provide an overview of CRAC channels in immune cell function.
  • To review the role of CRAC channels in preclinical models of immune diseases.
  • To discuss the outcomes of clinical trials involving CRAC channel inhibitors (CRACi).

Main Methods:

  • Review of existing literature on CRAC channel function in immunity.
  • Analysis of preclinical studies using knockout mice and CRAC inhibitors.
  • Examination of clinical trial data for CRAC inhibitors in inflammatory disorders.

Main Results:

  • CRAC channels are essential for the function of various immune cell types.
  • Preclinical studies confirm CRAC channel involvement in infection immunity, autoimmunity, allergy, and inflammation.
  • Clinical trials suggest CRAC inhibitors have potential as immunotherapies for inflammatory diseases.

Conclusions:

  • CRAC channels play a fundamental role in immune responses and disease pathogenesis.
  • CRAC inhibitors represent a promising therapeutic strategy for immune-related and inflammatory conditions.
  • Further clinical investigation of CRAC inhibitors is warranted for immunotherapy.